Stifel Nicolaus Lowers AnaptysBio (NASDAQ:ANAB) to Hold
Stifel Nicolaus cut shares of AnaptysBio (NASDAQ:ANAB) from a buy rating to a hold rating in a research note released on Friday, Briefing.com Automated Import reports. Stifel Nicolaus currently has $74.00 target price on the biotechnology company’s stock, down from their prior target price of $124.00.
Several other equities analysts also recently issued reports on ANAB. Guggenheim initiated coverage on shares of AnaptysBio in a report on Friday, February 22nd. They set a buy rating and a $135.00 price target for the company. Cantor Fitzgerald reissued a buy rating and set a $140.00 price target on shares of AnaptysBio in a report on Wednesday, February 27th. Zacks Investment Research downgraded shares of AnaptysBio from a hold rating to a sell rating in a report on Wednesday, February 27th. Wedbush reissued an outperform rating on shares of AnaptysBio in a report on Friday, March 1st. Finally, Credit Suisse Group downgraded shares of AnaptysBio from an outperform rating to a neutral rating and cut their price target for the company from $137.00 to $79.00 in a report on Friday. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. AnaptysBio currently has an average rating of Buy and an average price target of $111.25.
Shares of ANAB stock opened at $53.81 on Friday. AnaptysBio has a 12-month low of $53.45 and a 12-month high of $110.00. The company has a market cap of $1.60 billion, a P/E ratio of -21.52 and a beta of 1.97. The company’s 50-day moving average price is $71.29.
In other AnaptysBio news, insider Marco Londei sold 10,060 shares of the business’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $73.06, for a total value of $734,983.60. Following the completion of the transaction, the insider now directly owns 32,437 shares of the company’s stock, valued at $2,369,847.22. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Hamza Suria sold 22,428 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $73.76, for a total transaction of $1,654,289.28. Following the completion of the transaction, the chief executive officer now directly owns 31,524 shares of the company’s stock, valued at $2,325,210.24. The disclosure for this sale can be found here. Insiders own 14.00% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers grew its holdings in shares of AnaptysBio by 64.0% during the fourth quarter. Rhumbline Advisers now owns 28,181 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 11,001 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of AnaptysBio during the fourth quarter valued at approximately $126,000. State Board of Administration of Florida Retirement System grew its holdings in shares of AnaptysBio by 7.2% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 10,007 shares of the biotechnology company’s stock valued at $638,000 after purchasing an additional 674 shares during the last quarter. TD Asset Management Inc. grew its holdings in shares of AnaptysBio by 10.1% during the fourth quarter. TD Asset Management Inc. now owns 14,109 shares of the biotechnology company’s stock valued at $900,000 after purchasing an additional 1,300 shares during the last quarter. Finally, First Trust Advisors LP bought a new position in shares of AnaptysBio during the fourth quarter valued at approximately $957,000.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
Featured Article: Front-End Load
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.